These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1758527)

  • 1. Treatment of azotemic, nonoliguric, anemic patients with human recombinant erythropoietin raises whole-blood viscosity proportional to hematocrit.
    Brown CD; Kieran M; Thomas LL; Zhao ZH; Larsen R; Friedman EA
    Nephron; 1991; 59(3):394-8. PubMed ID: 1758527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and blood rheologic stability in erythropoietin-treated predialysis patients.
    Brown CD; Friedman EA
    Am J Nephrol; 1990; 10 Suppl 2():29-33. PubMed ID: 2260615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stable renal function and benign course in azotemic diabetics treated with erythropoietin for one year.
    Brown CD; Friedman EA
    Contrib Nephrol; 1991; 88():182-9; discussion 190-1. PubMed ID: 2040181
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythropoietin in diabetic macular edema and renal insufficiency.
    Friedman EA; Brown CD; Berman DH
    Am J Kidney Dis; 1995 Jul; 26(1):202-8. PubMed ID: 7611253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative contributions of body iron status and uremia severity to anemia in patients with advanced chronic renal failure.
    Ifudu O; Dawood M; Friedman EA
    Nephron; 1997; 77(3):315-8. PubMed ID: 9375826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hemo-rheologic changes following treatment with human recombinant erythropoietin in chronic hemodialysis patients].
    Melappioni M; Giansanti R; Boemi M; Baldassari M; Baldini S; Pierangeli T; Radicioni R; Fumelli P; Panichi N
    Minerva Urol Nefrol; 1992; 44(2):155-9. PubMed ID: 1411865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemorheological changes in uraemic children in response to erythropoietin treatment.
    Böhler T; Leo A; Linderkamp O; Braun A; Schärer K
    Nephrol Dial Transplant; 1993; 8(2):140-5. PubMed ID: 8384334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin therapy in chronic uremia: the impact of normalization of hematocrit.
    Murphy ST; Parfrey PS
    Curr Opin Nephrol Hypertens; 1999 Sep; 8(5):573-8. PubMed ID: 10541220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheological studies during treatment of renal anaemia with recombinant human erythropoietin.
    Macdougall IC; Davies ME; Hutton RD; Coles GA; Williams JD
    Br J Haematol; 1991 Apr; 77(4):550-8. PubMed ID: 2025581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Improvement of hemorheologic parameters in hemodialyzed patients treated with human recombinant erythropoietin].
    Delamaire M; Durand F; Hamel D; Joyeux V; Lepogamp P; Genetet B
    J Mal Vasc; 1991; 16(3):289-94. PubMed ID: 1940657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure.
    Haedersdal C; Mehlsen J; Stenver D; Nielsen B; Jeppesen L; Winther K
    Angiology; 1994 Mar; 45(3):231-4. PubMed ID: 8129205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone responses to growth hormone-releasing hormone and clonidine before and after erythropoietin therapy in CAPD patients.
    Díez J; Iglesias P; Sastre J; Méndez J; Selgas R; Gómez-Pan A
    Nephron; 1996; 74(3):548-54. PubMed ID: 8938679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacodynamic model of erythropoietin therapy for uremic anemia.
    Uehlinger DE; Gotch FA; Sheiner LB
    Clin Pharmacol Ther; 1992 Jan; 51(1):76-89. PubMed ID: 1732079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood rheology and hypertension in hemodialysis patients treated with erythropoietin.
    Schaefer RM; Leschke M; Strauer BE; Heidland A
    Am J Nephrol; 1988; 8(6):449-53. PubMed ID: 3218658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete correction of renal anemia by recombinant human erythropoietin.
    Ludat K; Paulitschke M; Riedel E; Hampl H
    Clin Nephrol; 2000 Feb; 53(1 Suppl):S42-9. PubMed ID: 10746805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of renal anaemia with recombinant human erythropoietin results in decreased red cell uptake of 45Ca.
    Linde T; Ronquist G; Sandhagen B; Wikström B; Frithz G; Pettersson L; Danielson BG
    Nephron; 1994; 68(4):419-26. PubMed ID: 7870225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
    Phair JP; Abels RI; McNeill MV; Sullivan DJ
    Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.
    Zwaginga JJ; IJsseldijk MJ; de Groot PG; Kooistra M; Vos J; van Es A; Koomans HA; Struyvenberg A; Sixma JJ
    Thromb Haemost; 1991 Dec; 66(6):638-47. PubMed ID: 1665596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of rhEPO therapy on erythrocyte rheology in dialysis patients with different target hematocrits.
    Paulitschke M; Ludat K; Riedel E; Hampl H
    Clin Nephrol; 2000 Feb; 53(1 Suppl):S36-41. PubMed ID: 10746804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.